Matches in Wikidata for { <http://www.wikidata.org/entity/Q96590306> ?p ?o ?g. }
Showing items 1 to 49 of
49
with 100 items per page.
- Q96590306 description "artículu científicu espublizáu en xunu de 2020" @default.
- Q96590306 description "scientific article published on 01 June 2020" @default.
- Q96590306 description "wetenschappelijk artikel" @default.
- Q96590306 description "наукова стаття, опублікована 1 червня 2020" @default.
- Q96590306 name "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis" @default.
- Q96590306 name "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis" @default.
- Q96590306 type Item @default.
- Q96590306 label "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis" @default.
- Q96590306 label "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis" @default.
- Q96590306 prefLabel "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis" @default.
- Q96590306 prefLabel "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis" @default.
- Q96590306 P1433 Q96590306-EB7AB148-9F0A-478A-B032-A1B214F0CEB8 @default.
- Q96590306 P1476 Q96590306-BC49703F-B0D0-4420-A403-568EB6874A21 @default.
- Q96590306 P2093 Q96590306-2A008FE6-1CEE-42B8-BE33-4DBEE1A02ACA @default.
- Q96590306 P2093 Q96590306-490356E3-3877-4C27-8328-46F418A92A9E @default.
- Q96590306 P2093 Q96590306-99B20421-3876-40EB-A688-DE7D0790673C @default.
- Q96590306 P2093 Q96590306-D871C96A-819E-4B09-B18A-9FE3928C5CB3 @default.
- Q96590306 P2093 Q96590306-FDE6D2F9-2FA3-4EC7-891C-909EB8E9B6F8 @default.
- Q96590306 P2093 Q96590306-FE79D324-1F93-4F47-9118-925FD31B0F8D @default.
- Q96590306 P304 Q96590306-26C602FE-682E-4ADD-A55A-862A5F03C87D @default.
- Q96590306 P31 Q96590306-E85B5811-64EE-4AE5-A33D-0E1AA74454D7 @default.
- Q96590306 P356 Q96590306-45DFA4FC-8B4B-4AEF-901E-6B96E6D89048 @default.
- Q96590306 P433 Q96590306-ED6A2494-BA09-4152-8421-64DF92D9FFC4 @default.
- Q96590306 P478 Q96590306-9A4C98BB-6161-4DA7-BD51-A5A32BDE3262 @default.
- Q96590306 P50 Q96590306-C6172042-DEA1-4CF0-BFC8-5DB973250F32 @default.
- Q96590306 P577 Q96590306-3E1C9346-67D2-41F2-AEDB-53CE1F41E602 @default.
- Q96590306 P698 Q96590306-5B375E96-10B3-43D7-8718-C387B33694F6 @default.
- Q96590306 P921 Q96590306-4D5547D6-A87D-4F25-B13E-F3A7B011D8E4 @default.
- Q96590306 P932 Q96590306-646EBF8C-A389-4AC1-BFD7-4461CB9666CA @default.
- Q96590306 P356 BLOODADVANCES.2019001329 @default.
- Q96590306 P698 32559295 @default.
- Q96590306 P1433 Q84365144 @default.
- Q96590306 P1476 "First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis" @default.
- Q96590306 P2093 "Annalisa Ferrero" @default.
- Q96590306 P2093 "Claudia Vener" @default.
- Q96590306 P2093 "Federico Ambrogi" @default.
- Q96590306 P2093 "Gabriella Pravettoni" @default.
- Q96590306 P2093 "Milena Sant" @default.
- Q96590306 P2093 "Rita Banzi" @default.
- Q96590306 P304 "2723-2735" @default.
- Q96590306 P31 Q13442814 @default.
- Q96590306 P356 "10.1182/BLOODADVANCES.2019001329" @default.
- Q96590306 P433 "12" @default.
- Q96590306 P478 "4" @default.
- Q96590306 P50 Q53342434 @default.
- Q96590306 P577 "2020-06-01T00:00:00Z" @default.
- Q96590306 P698 "32559295" @default.
- Q96590306 P921 Q177094 @default.
- Q96590306 P932 "7322957" @default.